Tooth extraction in a patient with juvenile osteoporosis and cardiovascular disease

Tsuyoshi Shimo*, Fumiya Harada, Kazuhiro Miyamoto, Tatsuji Odachi, Masahiro Ishikawa, Karnoon Shamsoon, Takashi Saito, Tomofumi Kawakami, Yoshihiro Abiko, Eiji Nakayama and Hiroki Nagayasu

1 Division of Reconstructive Surgery for Oral and Maxillofacial Region, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
2 Division of Oral and Maxillofacial Surgery, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan
3 Division of General Dental Sciences I, Department of Oral Rehabilitation, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan
4 Division of Clinical Cariology and Endodontology, Department of Oral Rehabilitation, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan
5 Division of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan
6 Division of Oral and Maxillofacial Radiology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan

Abstract
An association between bone metabolism and cardiovascular disease was recently reported. A 45-year-old Japanese man was referred to our hospital for the screening of an intraoral infection before surgery for mitral regurgitation. He had been diagnosed with juvenile osteoporosis and had taken the bisphosphonate alendronate sodium hydrate for >9 years. After a consultation with the patient’s primary care physician, we decided to withdraw the alendronate sodium hydrate for 2 months and restart it 1 month before and after the necessary tooth extraction. We performed extraction of the left-side upper and lower molars under local and general anesthesia. The bisphosphonate treatment was withheld before and after the tooth extraction for 3 months. However, at 6 months after the resumption of alendronate sodium hydrate, the hip fracture was caused by falling. In juvenile osteoporosis patients with a mental development delay who are at risk of falling, tooth extraction under continued bisphosphonate treatment is also necessary.

Case presentation
In September 2017, a 45-year-old Japanese man was referred to our hospital for the screening of an intraoral infection lesion before he was to undergo surgery for mitral regurgitation. His family history included the suicides of both his parents and his brothers. He had been diagnosed with juvenile osteoporosis and began treatment with a bisphosphonate (alendronate sodium, 35 mg/w orally) preparation to prevent fracture.

The panoramic X-ray at the patient’s first visit to our hospital is presented in Figure 1. The bone mineral density of the alveolar portion was high over the entire jaw. The left upper jaw 8 and the left lower
jaw 7 and 8 showed caries and tooth extraction due to poor cleaning performance. The risk of periodontal disease infection was large. A chest X-ray taken with the patient under general anesthesia at the screening in April 2018 is shown in Figure 2. Cardiac hypertrophy was recognized due to insufficient mitral regurgitation.

After a consultation with the patient’s primary care physician, we decided to withdraw the alendronate sodium hydrate for 2 months and restart it 1 month before and after the necessary tooth extraction. In April 2018, 2 g of amoxicillin was intravenously administered before the tooth extraction for the prevention of infective endocarditis against mitral regurgitation. Local anesthesia was administered while the patient was under general anesthesia, and the extraction of the left-side upper and lower molars was performed. The teeth roots were firmly adhered to the alveolar bone and root fractures occurred, but the teeth roots could be removed by a partial removal of the alveolar bone (Figure 3). Surgery for mitral regurgitation was performed after discharge, but 6 months after the resumption of alendronate sodium hydrate, the hip fracture was caused by falling. At 12 months’ post-extraction, there was no onset of anti-resorptive agent-related osteonecrosis of the jaw (ARONJ), and the patient’s course continued to be good.

Discussion

Postmenopausal osteoporosis causes an imbalance of osteogenesis as well as bone resorption enhancement due to a sharp decline in estrogen action after menopause, resulting in decreased bone mass and bone strength. Even in men, osteoblast differentiation is suppressed due to a decrease in the production of growth factors involved in the promotion of osteogenesis with aging; the synthesis of bone matrix proteins is also reduced. Since our patient has no disease causing secondary osteoporosis, it was diagnosed as juvenile osteoporosis. The cause of his juvenile osteoporosis is unknown.

In patients with osteoporosis-pseudoglioma syndrome, fracture due to a remarkable decrease in osteogenesis is observed in childhood. In these patients, it was shown that the mutation localized to the co-receptor LRP5 of Wnt, which revealed that the transmission of the canonical Wnt signal was hindered [6]. That report revealed that osteoporosis can be caused by a single genetic abnormality of LRP5, which is a co-receptor of Wnt (which is necessary for canonical Wnt signal transduction along with Frizzled).

In contrast, juvenile osteoporotic patients with LRP6 gene mutation are thought to transmit canonical Wnt signals as Wnt co-receptors as well. Mani et al. reported a familial cases of autosomal dominant inheritance with advanced juvenile osteoporosis and features of metabolic syndrome such as hypertension, diabetes, and hyperlipidemia and complicated with cardiovascular disease from an early stage. From the linkage analysis, the causative gene was mapped to the 12q chromosome, which was revealed to be due to the R661C point mutation of the LRP6 gene [4]. That report showed that abnormalities of single genes involved in the transmission of canonical Wnt signals can lead to early osteoporosis and metabolic syndrome and cardiovascular disorders.

An increasing number of genetic causes of osteoporosis have now been identified due to advances in genetic screening, with variants in genes with dominant, recessive and X-linked recessive inheritance patterns [7-11]. However, the association between PLS3 and cardiovascular disease is unknown, and the pathogenic role of PLS3 protein in bone diseases must be clarified [12]. In our present patient with juvenile osteoporosis, the association between his osteoporosis and cardiovascular disease is unknown, but genetic abnormality of Wnt signal is suspected. As the patient’s parents and brothers were deceased, a linkage analysis was not done.
In the 2014 guidelines from the American Association of Oral and Maxillofacial Surgeons (AAOMS), 4 years is indicated as a standard for the administration period of a bone resorption inhibitor related to antiresorptive osteonecrotic jaw (ARONJ) [13]. This is one of the reasons for the U.S. Food and Drug Administration's position that after tooth extraction, low-dose bisphosphonate for <2 years of treatment is safe, and the risk rises slightly for 2–4 years of treatment; the incidence rate increases for >4 years' treatment [13].

Our patient was treated with the bisphosphonate alendronate sodium hydrate for >9 years because of his high risk of fracture; we consulted with his primary care physician before the tooth extraction and withdrew the alendronate sodium hydrate for 2 months before performing the tooth extraction. After the epithelialization of the tooth extracted sockets at 1 month post-extraction, the alendronate sodium hydrate treatment was resumed. However, at 6 months after the resumption of alendronate sodium hydrate, the hip fracture was caused by falling. It is not yet clear whether alendronate sodium hydrate that has been administered for more than 4 years should be withheld both before and after tooth extraction. It is possible that bisphosphonate treatment should not be discontinued in patients at a high risk of falling, or in juvenile osteoporotic patients. We cannot deny the possibility that the hip fracture was caused by the alendronate sodium hydrate withdrawal for 3 months. In juvenile osteoporosis patients with a mental development delay who are at risk of falling, tooth extraction under continued bisphosphonate treatment is also necessary.

References